Evaluation of Novel Urinary Renal Biomarkers: Biological Variation and Reference Change Values

Toxicologic Pathology

Volumn 40, Issue 3, 2012, Pages 541-549

  Pinches, Mark D ^a   Betts, Catherine J ^a   Bickerton, Susan J ^a   Beattie, Laura ^a   Burdett, Lisa D ^a   Thomas, Helen T ^a   Derbyshire, Nicola A ^a   Moores, Michele ^a   Price, Sally A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

biomarkers; clinical pathology; kidney

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CALCIUM; CHOLESTEROL; CISPLATIN; CREATININE; CYSTATIN C; GLUCOSE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE YB1; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; POTASSIUM; PROTEIN; RENAL PAPILLARY ANTIGEN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HISTOPATHOLOGY; KIDNEY INJURY; MALE; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; REFERENCE VALUE; RELATIVE DENSITY; SODIUM BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; URINALYSIS; URINARY EXCRETION; URINE VOLUME; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY DISEASE; METABOLISM; URINE; WISTAR RAT;

ANIMALS; BIOLOGICAL MARKERS; CISPLATIN; CREATININE; FEMALE; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY DISEASES; MALE; RATS; RATS, WISTAR; REFERENCE VALUES;

EID: 84867446855     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311432436     Document Type: Review

References (26)

1. Abadie E. (2010). Qualification Opinion ILSI/HESI: Submission of Novel Renal Biomarkers of Toxicity. London, UK: European Medicines Agency.
2. Alessio L. Berlin A. Dell’Orto A. Toffoletto F. Ghezzi I. (1985). Reliability of urinary creatinine as a parameter used to adjust values of urinary biological indicators. Int Arch Occup Environ Health 55, 99–106.
3. Blank M. De Felice A. Goodsaid F. Harlow P. Hausner E. Jacobson-Kram D. Taylor W. Thompson A. Throckmorton D. Xiao S. (2008). Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the Predictive Safety Testing Consortium. BQRT. Center for Drug Evaluation and Research. U.S. Food and Drug Administration.
4. Fraser CG. The application of theoretical goals based on BV data in proficiency testing. Arch Pathol Lab Med 1988; 112, 404–15.
5. Fraser CG (1983) Desirable performance standards for clinical chemistry tests. Adv. Clin. Chem. 23, 299–339.
6. Fraser C. G. Harris E. K. (1989). Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 27, 409–37.
7. Fraser C. G. Petersen P. H. Ricos C. Haeckel R. (1992). Proposed quality specifications for the imprecision and inaccuracy of analytical systems for clinical chemistry. Eur J Clin Chem Clin Biochem 30, 311–17.
8. Garrett M. D. Workman P. (1999). Discovering novel chemotherapy drugs for the third millennium. Eur J Cancer 35, 2010–30.
9. Goodsaid F. M. Frueh F. W. Mattes W. (2008). Strategic paths for biomarker qualification. Toxicology 245, 219–23.
10. Han W. K. Bailly V. Abichandani R. Thadhani R. Bonventre J. V. (2002). Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int 62, 237–44.
11. Harris E. K. (1974). Effects of intra- and interindividual variation on the appropriate use of normal ranges. Clin Chem 20, 1535–42.
12. Heavner D. L. Morgan W. T. Sears S. B. Richardson J. D. Byrd G. D. Ogden M. W. (2006). Effect of creatinine and specific gravity normalization techniques on xenobiotic biomarkers in smokers' spot and 24-h urines. J Pharm Biomed Anal 40, 928–42.
13. HESI. Summary Report on the Proposed Qualification of Novel Renal Biomarkers of Toxicity. 2008 ILSI-HESI.
14. Jensen A. L. Aaes H. (1993). Critical differences of clinical chemical parameters in blood from dogs. Res Vet Sci 54, 10–14.
15. Jensen A. L. Pedersen H. D. Koch J. Aaes H. Flagstad A. (1993). Applicability of the critical difference. Zentralbl Veterinarmed A 40, 624–30.
16. Kinter S. H. (2005). Assessing renal effects of toxicants in vivo. In Toxicology of the Kidney. 3rd ed. Chap 3, 75–126 (Hook J. B. Tarloff J. B. Lash L. H., eds.). Boca Raton, FL, CRC Press.
17. Kola I. Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3, 711–15.
18. Lesco L. K. Atkinson A. J. Jr (2001).Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Ann Rev Pharmacol Toxicol 41, 347–66.
19. Loeb WF. Clinical chemistry of laboratory rodents and rabbits. In Kaneko JJ ed. Clinical chemistry of domestic animals. San Diego: Academic Press, 1989:869
20. Ozer J. S. Dieterle F. Troth S. Perentes E. Cordier A. Verdes P. Staedtler F. Mahl A. Grenet O. Roth D. R. Wahl D. Legay F. Holder D. Erdos Z. Vlasakova K. Jin H. Yu Y. Muniappa N. Forest T. Clouse H. K. Reynolds S. Bailey W. J. Thudium D. T. Topper M. J. Skopek T. R. Sina J. F. Glaab W. E. Vonderscher J. Maurer G. Chibout S. D. Sistare F. D. Gerhold D. L. (2010). A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nature Biotechnol 28, 486–94.
21. Pinches M. D. Betts C.J. Bickerton S.J. Beattie L. Burdett L.D. Thomas H.T. Derbyshire N. A. Moores M. (2012a). Evaluation of novel urinary renal biomarkers with a Cisplatin Model of kidney injury: Effects of collection period. Toxicol Pathol 40(3), 524–30.
22. Pinches M. D. Betts C.J. Bickerton S.J. Burdett L.D. Thomas H.T. Derbyshire N. A. Jones H. B. Moores M. (2012b). Evaluation of Novel Renal Biomarkers with a Cisplatin Model of Kidney Injury: Gender and Dosage Differences. Toxicol Pathol 40(3), 512–23.
23. Price S. A. Davies D. Rowlinson R. Copley C. G. Roche A. Falkenberg F. W. Riccardi D. Betton G. R. (2010). Characterization of renal papillary antigen 1 (RPA-1), a biomarker of renal papillary necrosis. Toxicol Pathol 38, 346–58.
24. Star R. A. (1998). Treatment of acute renal failure. Kidney Int 54, 1817–31.
25. Thrall M. A. (2004). Veterinary Hematology and Clinical Chemistry. Baltimore, MD: Lippincott Williams & Wilkins.
26. Yu Y. Jin H. Holder D. Ozer J. S. Villarreal S. Shughrue P. Shi S. Figueroa D. J. Clouse H. Su M. Muniappa N. Troth S. P. Bailey W. Seng J. Aslamkhan A. G. Thudium D. Sistare F. D. Gerhold D. L. (2010). Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nature Biotechnol 28, 470–77.